Taysha Gene Therapies, Inc. (TSHA) Return on equity 2022–2025
Taysha Gene Therapies, Inc. (TSHA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-44.1%FY2025 · since FY2022: -17493.6% → -44.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -44.1% | +80.7 pp |
| FY2024 | -124.8% | +24.0 pp |
| FY2023 | -148.9% | +17344.7 pp |
| FY2022 | -17493.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice